These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 10942635)

  • 1. Multi-drug resistant HIV-1.
    Omrani AS; Pillay D
    J Infect; 2000 Jul; 41(1):5-11. PubMed ID: 10942635
    [No Abstract]   [Full Text] [Related]  

  • 2. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors.
    Hecht FM; Grant RM; Petropoulos CJ; Dillon B; Chesney MA; Tian H; Hellmann NS; Bandrapalli NI; Digilio L; Branson B; Kahn JO
    N Engl J Med; 1998 Jul; 339(5):307-11. PubMed ID: 9682043
    [No Abstract]   [Full Text] [Related]  

  • 3. Viral resistance: a major challenge in managing HIV disease.
    Boucher CA; Reedijk M
    J Biol Regul Homeost Agents; 1995; 9(3):91-4. PubMed ID: 8782014
    [No Abstract]   [Full Text] [Related]  

  • 4. Current insights into reverse transcriptase inhibitor-associated resistance.
    Wainberg MA; White AJ
    Antivir Ther; 2001; 6 Suppl 2():11-9. PubMed ID: 11678474
    [No Abstract]   [Full Text] [Related]  

  • 5. [Recent challenges and progress in AIDS therapy--emergence of drug resistant HIV-1 variants].
    Mitsuya H
    Rinsho Ketsueki; 1999 Apr; 40(4):249-54. PubMed ID: 10355129
    [No Abstract]   [Full Text] [Related]  

  • 6. Limits of resistance testing.
    D'Aquila RT
    Antivir Ther; 2000 Mar; 5(1):71-6. PubMed ID: 10846596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV resistance: the new enemy.
    Colvin R
    Common Factor; 1997 Nov; (No 11):6-7. PubMed ID: 11364845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization.
    Kagan RM; Merigan TC; Winters MA; Heseltine PN
    Antivir Ther; 2004 Oct; 9(5):827-8. PubMed ID: 15535422
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical utility of resistance testing.
    Stebbing J; Gazzard BG
    J HIV Ther; 2002 Nov; 7(4):75-9. PubMed ID: 12733604
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiretroviral resistance.
    Geretti AM
    J HIV Ther; 2006 Dec; 11(4):72-3. PubMed ID: 17578209
    [No Abstract]   [Full Text] [Related]  

  • 11. Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant.
    Johnson VA; Petropoulos CJ; Woods CR; Hazelwood JD; Parkin NT; Hamilton CD; Fiscus SA
    J Infect Dis; 2001 Jun; 183(11):1688-93. PubMed ID: 11343221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revisiting the concept of a genetic barrier to resistance.
    Rusconi S
    J HIV Ther; 2006 Dec; 11(4):81-3. PubMed ID: 17578211
    [No Abstract]   [Full Text] [Related]  

  • 13. Interpretation of resistance assay results.
    Miller V
    Antivir Ther; 2001; 6 Suppl 2():1-9. PubMed ID: 11678473
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART.
    Caride E; Brindeiro R; Hertogs K; Larder B; Dehertogh P; Machado E; de Sá CA; Eyer-Silva WA; Sion FS; Passioni LF; Menezes JA; Calazans AR; Tanuri A
    Virology; 2000 Sep; 275(1):107-15. PubMed ID: 11017792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary drug resistance in antiretroviral-naïve injection drug users.
    Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
    Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding transmitted HIV resistance through the experience in the USA.
    Taiwo B
    Int J Infect Dis; 2009 Sep; 13(5):552-9. PubMed ID: 19136289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of drug resistance mutations in Spain among both naive and pretreated patients.
    Soriano V
    Antivir Ther; 1999; 4 Suppl 3():57-63. PubMed ID: 16021872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of HIV-1 multidrug-resistant genotypes during combination therapy and after the cessation of antiretroviral drugs.
    Yahi N; Tourrès C; Tivoli N; Colson P; Dhiver C; Quinson AM; Tamalet C
    AIDS; 2000 Dec; 14(18):2943-5. PubMed ID: 11153678
    [No Abstract]   [Full Text] [Related]  

  • 19. The clinical significance of viral fitness.
    Geretti AM
    J HIV Ther; 2005 Mar; 10(1):6-10. PubMed ID: 15951728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V; Larder BA
    Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.